VCYT logo

Veracyte (VCYT) Company Overview

Profile

Full Name:

Veracyte, Inc.

Sector:

Healthcare

Industry:

Diagnostics & Research

Country:

United States

IPO:

October 30, 2013

Indexes:

Not included

Website:

http://www.veracyte.com

Description:

Veracyte, Inc. is a leading company in the field of genomic diagnostics in the USA and abroad. The company was previously known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was registered in 2006, with headquarters located in South San Francisco, California. Veracyte, Inc. conducts a series of genomic tests for the detection of cancer and idiopathic pulmonary fibrosis in a CLIA-certified laboratory. The company uses advanced scientific methods such as whole transcriptome RNA sequencing and machine learning to develop tests and optimize analysis results.

Key Details

Price

$40.49

Market Cap

$3.14 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$361.05 M(+21.76% YoY)

Annual EPS

-$1.02(-100.00% YoY)

PE Ratio

-

Annual ROE

-7.02%

Annual Debt To Equity

0.00

Beta

1.61

Events Calendar

Earnings

Next earnings date:

Feb 24, 2025

Recent quarterly earnings:

Nov 6, 2024

Recent annual earnings:

Feb 22, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 29, 25 Needham
Buy
Dec 5, 24 Goldman Sachs
Neutral
Nov 18, 24 Morgan Stanley
Underweight
Nov 8, 24 Scotiabank
Sector Outperform
Nov 7, 24 UBS
Buy
Nov 7, 24 Needham
Buy
Nov 7, 24 Goldman Sachs
Buy
Oct 17, 24 Leerink Partners
Outperform
Oct 16, 24 UBS
Buy
Oct 10, 24 Guggenheim
Buy

Screeners with VCYT included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks with high beta
Most recommended stocks
Best performing stocks last 3 months
Best performing stocks last 5 years
Stocks below analysts price target
Healthcare sector
All stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$40.49
VCYT price is $40.49

Price All-time High

$81.38
VCYT price is currently -50.25% below its historical high of $81.38

Price Analysts Target

$46.00
VCYT price is currently -11.98% lower than the consensus analysts' forecast

Price Most Recent Change

+0.6%
VCYT price was up +0.6% on Feb 21, 2025

Price YTD Change

+3.82%
VCYT price is up +3.82% since January 1st

Price 3-Year Change

+59.85%
VCYT price is up +59.85% over the past 3 years

Market cap

Market Cap

$3.14 B
VCYT market capitalization is $3.14 billion

Market Cap 3-Year Change

+74.18%
VCYT market capitalization is up +74.18% over the past 3 years

Market Cap All-time High

$5.43 B
VCYT market capitalization is currently -42.23% below its historical high of $5.43 billion

Market Cap Sector Rank

85.37%
VCYT market capitalization is higher than 85.37% of companies in Healthcare sector

Technical

Beta

1.61
VCYT beta is 1.61

200-day SMA

$32.45
VCYT price is currently +24.77% above its 200-day simple moving average

14-day RSI

40.69
VCYT 14-day relative strength index is 40.69

30-day Relative Volume

1.02
VCYT 30-day relative volume is 1.02

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$361.05 M
VCYT annual revenue is $361.05 million

Annual Revenue Analysts Estimate

$443.25 M
VCYT annual revenue is currently -18.54% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+21.76%
VCYT annual revenue is up +21.76% year-on-year

Annual Revenue Sector Rank

72.1%
VCYT annual revenue is higher than 72.1% of companies in Healthcare sector

Profit

Annual Gross Profit

$248.15 M
VCYT annual gross profit is $248.15 million

Annual Gross Margin

68.73%
VCYT annual gross profit margin is 68.73%

Annual Operating Profit

-$17.45 M
VCYT annual operating income is -$17.45 million

Annual Operating Margin

-4.83%
VCYT annual operating profit margin is -4.83%

Annual Net Income

-$74.40 M
VCYT annual net profit is -$74.40 million

Annual Net Margin

-20.61%
VCYT annual net profit margin is -20.61%

EPS

Annual EPS

-$1.02
VCYT annual earnings per share is -$1.02

Annual EPS Analysts Estimate

$1.01
VCYT annual earnings per share is currently -200.58% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

-100%
VCYT annual earnings per share is down -100% year-on-year

Annual EPS Sector Rank

60.62%
VCYT annual earnings per share is higher than 60.62% of companies in Healthcare sector

ROA & ROE

Annual ROA

-6.55%
VCYT annual return on assets is -6.55%

Annual ROE

-7.02%
VCYT annual return on equity is -7.02%

EBIT & EBITDA

Annual EBIT

-$17.45 M
VCYT annual earnings before interest & taxes is -$17.45 million

Annual EBITDA

$9.74 M
VCYT annual EBITDA is $9.74 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

-
VCYT price to earnings ratio value is unknown

PE Ratio Sector Rank

-
VCYT price to earnings ratio is unknown

PB Ratio

PB Ratio

2.67
VCYT price to book ratio is 2.67

PB Ratio Sector Rank

65.93%
VCYT price to book ratio is higher than 65.93% of companies in Healthcare sector

PS Ratio

PS Ratio

7.38
VCYT price to sales ratio is 7.38

PS Ratio Sector Rank

70.82%
VCYT price to sales ratio is higher than 70.82% of companies in Healthcare sector

Enterprise value

Enterprise Value

$2.88 B
VCYT enterprise value is $2.88 billion

Enterprise Value Sector Rank

85.84%
VCYT enterprise value is higher than 85.84% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

99.86
VCYT EV/EBITDA is 99.86

EV/EBITDA Sector Rank

98.48%
VCYT EV/EBITDA is higher than 98.48% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.66
VCYT annual current ratio is 4.66

Annual Quick Ratio

4.40
VCYT annual quick ratio is 4.40

Leverage

Annual Debt To Equity

0.00
VCYT annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-1163.07
VCYT annual interest coverage ratio is -1163.07

Risk & Stability

Piotroski F-Score

5
VCYT piotroski f-score is 5

Altman Z-Score

26.52
VCYT altman z-score is 26.52

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$1.11 B
VCYT annual total assets is $1.11 billion

Annual Non Current Assets

$829.28 M
VCYT annual long term assets is $829.28 million

Annual Current Assets

$285.62 M
VCYT annual total current assets is $285.62 million

Annual Cash & Cash Equivalents

$216.45 M
VCYT annual cash & cash equivalents is $216.45 million

Equity

Annual Book Value

$1.04 B
VCYT annual book value is $1.04 billion

Annual Working Capital

$224.38 M
VCYT annual working capital is $224.38 million

Liabilities

Annual Total Liabilities

$70.80 M
VCYT annual total liabilities is $70.80 million

Annual Total Long Term Liabilities

$9.56 M
VCYT annual total long term liabilities is $9.56 million

Annual Current Liabilities

$61.24 M
VCYT annual total current liabilities is $61.24 million

Annual Accounts Payable

$12.94 M
VCYT annual accounts payable is $12.94 million

Debt

Annual Total Debt

$12.63 M
VCYT annual total debt is $12.63 million

Annual Total Debt 1-Year Change

-14.19%
VCYT annual total debt is down -14.19% year-on-year

Annual Long Term Debt

$7.53 M
VCYT annual long term debt is $7.53 million

Annual Short Term Debt

$5.11 M
VCYT annual short term debt is $5.11 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$378.50 M
VCYT annual total expenses is $378.50 million

Annual Operating Expenses

$265.59 M
VCYT annual total operating expenses is $265.59 million

Annual Cost Of Goods Sold

$112.90 M
VCYT annual cost of goods sold is $112.90 million

Annual SGA

$187.72 M
VCYT annual SGA is $187.72 million

Annual D&A

$27.19 M
VCYT annual depreciation & amortization is $27.19 million

Annual Interest Expense

$15.00 K
VCYT annual interest expense is $15.00 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$44.22 M
VCYT annual cash flow from operations is $44.22 million

Annual CFO 1-Year Change

+486.89%
VCYT annual cash flow from operations is up +486.89% year-on-year

Annual CFI

$15.11 M
VCYT annual cash flow from investing activities is $15.11 million

Annual CFI 1-Year Change

+151.42%
VCYT annual cash flow from investing activities is up +151.42% year-on-year

Annual CFF

$2.84 M
VCYT annual cash flow from financing activities is $2.84 million

Annual CFF 1-Year Change

-18.8%
VCYT annual cash flow from financing activities is down -18.8% year-on-year

Free CashFlow

Annual FCF

$34.26 M
VCYT annual free cash flow is $34.26 million

Annual FCF 1-Year Change

+3478.8%
VCYT annual free cash flow is up +3478.8% year-on-year

CAPEX

Annual CAPEX

$9.96 M
VCYT annual capital expenditures is $9.96 million

Annual CAPEX 1-Year Change

+16.52%
VCYT annual capital expenditures is up +16.52% year-on-year

Institutional Ownership

Similar stocks

HAE logo
Haemonetics (HAE)
SGRY logo
Surgery Partners (SGRY)
MRUS logo
Merus NV (MRUS)
PRVA logo
Privia Health (PRVA)
DNLI logo
Denali Therapeutics (DNLI)
Metsera (MTSR)
ACAD logo
ACADIA Pharmaceuticals (ACAD)
ACLX logo
Arcellx (ACLX)
AMED logo
Amedisys (AMED)

FAQ

  • What is the ticker symbol for Veracyte?
  • Does Veracyte pay dividends?
  • What sector is Veracyte in?
  • What industry is Veracyte in?
  • What country is Veracyte based in?
  • When did Veracyte go public?
  • Is Veracyte in the S&P 500?
  • Is Veracyte in the NASDAQ 100?
  • Is Veracyte in the Dow Jones?
  • When was Veracyte's last earnings report?
  • When does Veracyte report earnings?
  • Should I buy Veracyte stock now?

What is the ticker symbol for Veracyte?

The ticker symbol for Veracyte is NASDAQ:VCYT

Does Veracyte pay dividends?

No, Veracyte does not pay dividends

What sector is Veracyte in?

Veracyte is in the Healthcare sector

What industry is Veracyte in?

Veracyte is in the Diagnostics & Research industry

What country is Veracyte based in?

Veracyte is headquartered in United States

When did Veracyte go public?

Veracyte's initial public offering (IPO) was on October 30, 2013

Is Veracyte in the S&P 500?

No, Veracyte is not included in the S&P 500 index

Is Veracyte in the NASDAQ 100?

No, Veracyte is not included in the NASDAQ 100 index

Is Veracyte in the Dow Jones?

No, Veracyte is not included in the Dow Jones index

When was Veracyte's last earnings report?

Veracyte's most recent earnings report was on Nov 6, 2024

When does Veracyte report earnings?

The next expected earnings date for Veracyte is Feb 24, 2025

Should I buy Veracyte stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions